Prexasertib, a CHK1 inhibitor, has been demonstrated to elicit a strong anti-tumour response in preclinical models of DSRCT, malignant rhabdoid tumour, and rhabdomyosarcoma but variable responses in Ewing sarcoma and osteosarcoma [205]. Here, CHEK1 is linked to rhabdomyosarcoma.